Community advisory boards (CABs) are community engagement platforms, comprised of treatment advocates and community leaders with lived experience to review the state of treatment research, contribute to research protocols, engage in the research and development process, and meet with industry and developers about cost, pricing, and access plans.
Call for New Global Long-Acting Technologies CAB Members from Asian, Central African, Eastern European, MENA, and Latin American Countries
TAG and AfroCAB announce an expanded call for a new cross-disease LAT CAB focused on malaria, hepatitis C, and latent TB. Apply now! Applications accepted on a rolling basis. More
A patent landscape, released by TAG, investigates potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines. More
The HCV World CAB interacted with pharmaceutical and diagnostics companies that produce HCV treatment and tests to understand their access, licensing, and pricing strategies, particularly in high-burden, low- and middle-income countries.
Treatment activists held the first global LMIC-focused dialogue with pharmaceutical companies that produce HCV treatment, co-organized by TAG and the Asia Pacific Network of PLHA. More
The LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, and latent TB infection.
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, and LTBI. More
In reflection of World Malaria Day, LAT CAB issues a statement calling for a multi-pronged malaria eradication approach. More